Quadrivalent influenza vaccine

ApprovedVaccine

Quadrivalent influenza vaccine is one of 83 biologic programs targeting Multiple Sclerosis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple SclerosisActive, not recruiting

COVID-19Active, not recruiting

InfluenzaActive, not recruiting

Multiple SclerosisApproved

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

InfluenzaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Quadrivalent influenza vaccine

Sanofi

Approved

1 2

Spikevax

Moderna

Preclinical

21 3

Bnt162b2

BioNTech

Preclinical

29 4

COVID-19 Vaccine

Moderna

Preclinical

27 5

Biaxin

AbbVie

Preclinical

2 6

Stivarga

Bayer

Preclinical

1 7

Aimovig

Amgen

Preclinical

1 8

Aldactone

Pfizer

Preclinical

1 9

Nexavar

Bayer

Preclinical

1 10

Singulair

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Influenza30 trials

A Clinical Trial of A Quadrivalent Influenza Vaccine

Completed·SShanghai Institute Of Biological Products·Phase 3·NCT03744104·2,688 enrolled

Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age

Completed· Sanofi logo

Sanofi·Phase 3·NCT04210349·7,106 enrolled

Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines

Completed·—·Phase 4·NCT05970887·154 enrolled

Show 27 more trials

This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.

Completed· Pfizer logo

Pfizer··NCT05858450·3,442,996 enrolled

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22

Completed· Sanofi logo

Sanofi··NCT05078060·1,804 enrolled

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23

Completed· Sanofi logo

Sanofi··NCT05568979·1,001 enrolled

A Clinical Trial of an Inactivated Quadrivalent Influenza Vaccine in Chinese Children Aged 3 to 8 Years

Completed·JJiangsu Province Centers for Disease Control and Prevention·Phase 4·NCT05313893·252 enrolled

Safety of a Quadrivalent Influenza Vaccine (VaxigripTetra™) in Subjects Aged 6 Months and Older in Vietnam

Completed· Sanofi logo

Sanofi·Phase 3·NCT03765437·230 enrolled

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)

Completed· Sinovac Biotech Co., Ltd logo

Sinovac Biotech Co., Ltd·Phase 3·NCT03859141·2,340 enrolled

A Study About Modified RNA Vaccines Against Influenza in Healthy Adults

Completed· Pfizer logo

Pfizer·Phase 2·NCT06436703·1,202 enrolled

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza

Completed· Pfizer logo

Pfizer·Phase 1·NCT05227001·440 enrolled

Study of a Quadrivalent Influenza Vaccine Administered Intramuscularly in Children/Adolescents and Adults

Completed· Sanofi logo

Sanofi·Phase 3·NCT01481454·1,701 enrolled

Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry

Completed· Sanofi logo

Sanofi··NCT01945424·244 enrolled

A Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

Completed· Sinovac Biotech Co., Ltd logo

Sinovac Biotech Co., Ltd·Phase 3·NCT05245552·217 enrolled

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

Completed·SSeqirus·Phase 3·NCT02214225·3,484 enrolled

Lot-to-lot Consistency of Quadrivalent Influenza Vaccine (Split Virion), Inactivated

Completed· Sinovac Biotech Co., Ltd logo

Sinovac Biotech Co., Ltd·Phase 4·NCT05512494·1,260 enrolled

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years

Terminated· Sanofi logo

Sanofi·Phase 3·NCT05513391·366 enrolled

Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .

Completed·BButantan Institute·Phase 3·NCT05779020·1,373 enrolled

A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

Completed· Sinovac Biotech Co., Ltd logo

Sinovac Biotech Co., Ltd·Phase 3·NCT06049927·3,300 enrolled

Study of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan

Completed· Sanofi logo

Sanofi·Phase 3·NCT01967784·100 enrolled

A Clinical Trial of an Inactivated Quadrivalent Influenza Vaccine in Chinese Children Aged 3 to 8 Years

Unknown status·JJiangsu Province Centers for Disease Control and Prevention·Phase 4·NCT05144464·240 enrolled

Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population

Completed·PPT Bio Farma·Phase 2·NCT03336593·810 enrolled

A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.

Completed·SShanghai Institute Of Biological Products·Phase 1·NCT06342349·300 enrolled

Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years

Completed·SShanghai Institute Of Biological Products·Phase 4·NCT05138705·380 enrolled

A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older

Completed·JJiangsu Province Centers for Disease Control and Prevention·Phase 3·NCT02710409·3,664 enrolled

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)

Completed· Sinovac Biotech Co., Ltd logo

Sinovac Biotech Co., Ltd·Phase 3·NCT03853993·2,380 enrolled

A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine)

Completed·GGreen Cross Corporation·Phase 1/2·NCT02121782·84 enrolled

Cost-effectiveness of the Influenza Vaccination

Unknown status·IInternational Centre for Diarrhoeal Disease Research, Bangladesh·Phase 4·NCT05996549·2,567 enrolled

A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older

Completed· Pfizer logo

Pfizer·Phase 3·NCT05540522·45,789 enrolled

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24

Completed· Sanofi logo

Sanofi··NCT06059456·2,078 enrolled

Multiple Sclerosis1 trial

A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab

Completed· Novartis logo

Novartis·Phase 4·NCT04667117·63 enrolled

Stem Cell Transplant1 trial

High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT02860039·170 enrolled

COVID-191 trial

COVID-19: A Trial Studying the SARS-CoV-2 mRNA Vaccine CVnCoV to Learn About the Immune Response, the Safety, and the Degree of Typical Vaccination Reactions When CVnCoV is Given at the Same Time as a Flu Vaccine Compared to When the Vaccines Are Separately Given in Adults 60 Years of Age and Older

Withdrawn· Bayer logo

Bayer·Phase 3·NCT04848467

Pregnant Women1 trial

Optimising Protection for Pregnant Women and Infants With Maternal Vaccination

Unknown status·WWomen's and Children's Hospital, Australia··NCT03457194·73 enrolled

Sources

References

[1]
ClinicalTrials.gov — 34 trial records for Quadrivalent influenza vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Quadrivalent influenza vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Quadrivalent influenza vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: Sanofi

Quadrivalent influenza vaccine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Influenza30 trials

Multiple Sclerosis1 trial

Stem Cell Transplant1 trial

COVID-191 trial

Pregnant Women1 trial

References

Drug Info

Quick Facts

Related News